Acute respiratory failure – European Clinical Trials Information Network

Study of High-Flow Nasal Oxygen During Intubation in Intensive Care Patients with Low Blood Oxygen Levels

Wed, 29 Apr 2026 15:07:26 +0000

This study focuses on patients with hypoxemic acute respiratory failure, a condition where the body doesn’t get enough oxygen, causing breathing difficulties and low oxygen levels in the blood. The research examines the use of high-flow nasal oxygenation during a medical procedure called intubation, where a breathing tube is inserted into the airway. The main treatment being studied is medical oxygen delivered through specialized equipment.

The purpose of the study is to determine if providing oxygen through the nose during the intubation procedure can reduce the occurrence of dangerously low oxygen levels in patients who are already having difficulty breathing. Patients will be divided into two groups – one receiving the nasal oxygen treatment during intubation, and another group receiving standard care without additional oxygen.

During the study, medical staff will monitor oxygen levels in the blood and track any complications that may occur during and after the breathing tube placement. The treatment involves using up to 60 liters of oxygen per day through specialized breathing equipment. Patients will be followed for 28 days after the procedure to assess their recovery.

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Wed, 29 Apr 2026 15:03:21 +0000

This clinical trial is focused on studying the effects of a treatment for patients who are hospitalized due to a severe viral lung infection and require extra oxygen to help them breathe. The treatment being tested is called Tozorakimab, also known by its code name MEDI3506. It is a solution that is given through an injection into the veins. The study will compare the effects of Tozorakimab with a placebo to see how well it works in preventing serious outcomes like death or the need for advanced breathing support by Day 28 of the study.

The purpose of this study is to evaluate the safety and effectiveness of Tozorakimab in helping patients recover from severe viral lung infections. Participants in the study will receive either the Tozorakimab treatment or a placebo, in addition to the standard care they are already receiving. The study will monitor the participants over a period of time to see how many days they are alive and free from needing intensive care or extra oxygen, as well as other health outcomes.

Throughout the study, researchers will collect information on various health measures, such as the number of days participants are alive and not in the intensive care unit, and the time it takes for them to recover enough to stop needing extra oxygen. The study aims to provide valuable insights into how Tozorakimab can help improve the health and recovery of patients with severe viral lung infections.

Study on the Effects of Dexamethasone in Adults with Acute Respiratory Failure Due to Infections, Including COVID-19

Wed, 29 Apr 2026 15:02:49 +0000

This clinical trial is focused on studying the effects of the medication dexamethasone in patients who are experiencing Acute Hypoxemic Respiratory Failure, which can occur due to infections like COVID-19. Acute Hypoxemic Respiratory Failure is a condition where the lungs cannot provide enough oxygen to the blood, often requiring support from a ventilator. The trial aims to compare the outcomes of using higher doses versus lower doses of dexamethasone, a medication that helps reduce inflammation, in these patients.

The purpose of the study is to understand how different doses of dexamethasone affect the number of deaths within 60 days and the number of days patients can live without needing a ventilator within 28 days. The study will involve patients who are already on ventilators due to severe breathing difficulties caused by infections. Participants will receive either a higher or lower dose of dexamethasone through an injection, and their progress will be monitored over time to see how the treatment impacts their recovery and survival.

Throughout the study, researchers will collect information on various outcomes, such as the number of days patients spend on ventilators, their length of stay in the hospital, and their overall survival rates. This information will help determine the most effective dose of dexamethasone for treating patients with severe respiratory failure due to infections. The study will also track the presence of viral RNA over time to understand the infection’s progression and response to treatment.

Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support

Wed, 29 Apr 2026 15:02:30 +0000

This clinical trial is focused on studying different treatment strategies for patients who need support from a machine called Extracorporeal Membrane Oxygenation, or ECMO. ECMO is used in serious conditions like Respiratory Insufficiency, Respiratory Failure, Circulatory Failure, and Acute Respiratory Distress Syndrome. The study will compare three medications that help prevent blood clots, which are a common risk during ECMO therapy. These medications are Unfractionated Heparin, Argatroban, and Low-molecular-weight Heparin (also known as Enoxaparin).

The purpose of the study is to see how these medications affect the occurrence of blood clots during ECMO therapy. Participants will be randomly assigned to receive one of the three medications. The study will monitor the incidence of blood clots, such as pulmonary embolism and deep vein thrombosis, as well as any bleeding events. The study will last for a period of up to six months for each participant.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the medication they are receiving. The goal is to determine which medication is most effective in preventing blood clots without causing significant bleeding. This information will help improve treatment strategies for patients requiring ECMO support in the future.

Study on Weaning Patients with Acute Respiratory Failure from High-Flow Nasal Oxygen Therapy Using Oxygen

Wed, 29 Apr 2026 14:26:53 +0000

This clinical trial is focused on patients experiencing a condition known as acute respiratory failure, which occurs when the lungs cannot provide enough oxygen to the body’s organs. The study is investigating a treatment method called High-Flow Nasal Oxygen Therapy, which delivers oxygen through a nasal cannula at a high flow rate to help patients breathe more easily. The main goal of the study is to determine if using a specific protocol can help patients successfully stop using this therapy within seven days.

Participants in the study will receive either the standard care or follow a new protocol designed to help them gradually reduce their dependence on high-flow nasal oxygen. The study will monitor patients over a period of up to 28 days to see how well they can be weaned off the therapy. Researchers will also track other outcomes, such as the need for additional breathing support, the length of stay in the intensive care unit, and overall recovery progress.

The study aims to improve the process of weaning patients from high-flow nasal oxygen therapy, potentially leading to better recovery outcomes for those with acute respiratory failure. By understanding how to effectively reduce the use of this therapy, the study hopes to enhance patient care and support recovery in the intensive care setting.